Kamil GÖNDEREN, İrem BİLGETEKİN, Aysun GÖNDEREN, Mehmet YILDIZ

Yeni tanı konulmuş glukoz metabolizma bozukluğu olan hastalarda serum visfatin konsatrasyonun değerlendirilmesi

Amaç: Visfatin, visseral adipoz doku tarafından salgılanan, insülin-mimetik etkileri olan ve plazma glukoz seviyelerini düşüren hücre içi bir enzimdir. Yeni tanı konulan glukoz metabolizma bozukluklarında visfatinin rolü ile ilgili yapılan çalışmalar sınırlıdır. Bu çalışmanın amacı bozulmuş açlık glukozu ve bozulmuş glukoz toleransı olan hastalarda visfatin serum konsantrasyonunu değerlendirmektir. Gereç ve yöntem: Anormal glukoz metabolizması tanısı alan 57 hasta, oral glukoz tolerans testi (OGTT) sonuçlarına göre bozulmuş açlık glukozu (BAG) (n = 39) ve BAG+ bozulmuş glukoz toleransı (BGT) (n = 18) olarak alt gruplara ayrıldı. Kontrol grubu, normal glukoz toleransı olan ve herhangi bir metabolik bozukluğu olmayan 44 sağlıklı bireyden oluşuyordu. Tüm katılımcıların serum lipidleri, yüksek duyarlı CRP, ürik asit, glikolize hemoglobin (HbA1c) ve serum visfatin düzeyleri ölçüldü. Bulgular: BAG grubunun visfatin düzeyi 93.92 ± 12.95, BAG + BGT grubunun 37.79 ± 29.36, kontrol grubunun 43.96 ± 38.57 idi. Grupların serum visfatin düzeyleri arasında istatistiksel olarak anlamlı fark vardı (p <0.001). BAG grubunun ortalama visfatin düzeyi, BAG + BGT ve kontrol gruplarından istatistiksel olarak daha yüksekti (sırasıyla p <0.001, p <0.001). BAG + BGT grubunun visfatin düzeyi kontrol grubununkinden düşüktü, ancak aradaki fark istatistiksel olarak anlamlı değildi (p = 0.785). Visfatin düzeyleri toplam kolesterol, HDL, LDL, hsCRP, ferritin ve HbA1c düzeyleri ile negatif korelasyon gösterdi, TG, HOMA-ir ve BMI değerleri ile pozitif korelasyon gösterdi, ancak bu iliĢkiler istatistiksel olarak anlamlı değildi. Sonuç: BAG olan hastaların visfatin düzeyleri sağlıklı kontrollerden daha yüksekti, ancak visfatin seviyeleri HOMA-ir, BMI, TG, HDL, LDL, hsCRP, ferritin, MPV, HbA1c ve kolesterol düzeyleri arasında anlamlı korelasyon saptanmadı.

Anahtar Kelimeler:

Visfatin, Impaired Fasting Glucose

Visfatin concentration in patients with newly-diagnosed glucose metabolism disorders

ABSTRACT Purpose: Visfatin, protein secreted by visceral adipose tissue, visfatin is an intracellular enzyme that has insulin-mimetic effects and lowers plasma glucose levels. Data about the role of visfatin in newly diagnosed glucose metabolism abnormalities are limited. The aim of the work was to assess serum concentration of visfatin in impaired fasting glucose and impaired glucose tolerance. Materials and Methods: 57 patients with diagnosis of abnormal glucose metabolism were divided into the subgroups according to the oral glucose tolerance test (OGTT) results as impaired fasting glucose(IFG) (n=39) and IFG+ impaired glucose tolerance (IGT) (n=18). The control group consisted of 44 healthy controls with normal glucose tolerance and without any metabolic disorders. Serum lipids, high sensitive CRP, uric acide, glycated haemoglobin (HbA1c) and serum visfatin levels were measured in all participants. Results: The mean visfatin level of IFG group was 93.92±12.95, IFG+IGT group was 37.79±29.36 and control group was 43.96±38.57. There was statistically significant difference between serum visfatin levels of the groups (p<0.001). Mean visfatin level of IFG group was statistically higher than IFG+IGT and control groups (respectively p<0.001, p<0.001). Mean visfatin level of IFG+IGT group was lower than the control group however, the difference was not statistically significant (p=0.785). Visfatin levels were negatively correlated with total cholesterol, HDL, LDL, hsCRP, ferritin and HbA1c levels, positively correlated with TG, HOMA-ir and BMI values, however these relationships were not statistically significant. Conclusion: Visfatin levels of patients with IFG were higher than healthy controls however, visfatin levels were not correlated with HOMA-ir, BMI, TG, HDL, LDL, hsCRP, ferritin, MPV, HbA1c and cholesterol levels.

Keywords:

Visfatin, Impaired Fasting Glucose,

PDF

___

Genuth S, Alberti KG, Bennett P et al. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160–3167. doi: 10.2337/diacare.26.11.3160.
Temd diabetes mellitus ve komplikasyonlarının tanı, tedavi ve izlem kılavuzu-2018
S Ognjanovic, S Bao, S Y Yamamoto, J Garibay-Tupas, B Samal and G D Bryant-Greenwood. Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. J. Mol. Endocrinol. 2001; 26:107–117.
Matthews DR, Hasker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in men. Diabetologia 1985, 28: 412-9.
Lopez-Bermejo A, Chico-Julia B, Fernandez-Balsells M, et al. Serum visfatin increases with progressive beta-cell deterioration. Diabetes 2006; 55(10): 2871–2875.
Brown JE, Onyango DJ, Ramanjaneya M, et al. Visfatin regulates insulin secretion, insulin receptor signalling and mRNA expression of diabetes-related genes in Mouse pancreatic beta-cells. J Mol Endocrinol 2010; 44: 171–178.
Chen MP, Chung FM, Chang DM, et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006, 91: 295-9.
Krzyzanowska K, Krugluger W, Mittermayer F, et al. Increased Visfatin visfatin concentrations in women with gestational diabetes mellitus. Clin Sci (Lond) 2006, 110: 605-9.
Stephens JM, Vidal-Puig AJ. An update on visfatin/pre-B cell colonyenhancing factor, a ubiquitously expressed, illusive cytokine that is regulated in obesity. Curr Opin Lipidol 2006; 17: 128–131. doi: 10.1097/01. mol.0000217893.77746.4b.
Chang YH, Chang DM, Lin KC et al. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes Metab Res Rev 2011; 27: 515–527. doi: 10.1002/dmrr.1201.
Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes Metab Res Rev 2011; 27: 515–527.
Toruner F, Altinova AE, Bukan N. et al. Plasma visfatin concentrations in subjects with type 1 diabetes mellitus. Horm Res 2009;72:33-37.
Nüsken KD, Nüsken E, Petrasch M et al. Preanalytical influences on the measurement of visfatin by enzyme immuno assay. Clin Chim Acta 2007;382: 154–156. doi: 10.1016/j.cca.2007.04.004.
Körner A, Garten A, Blüher M et al. Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab 2007; 92: 4783–4791. doi: http: //dx.doi.org/10.1210/jc.2007-1304.
Zahorska-Markiewicz B, Olszanecka-Glinianowicz M,Janowska J, et al. Serum concentration of visfatin in obese women. Metabolism 2007;56:1131-1134.
Kamińska A, Kopczyńska E, Bronisz A, et al. An evaluation of visfatin levels in obese subjects. Endokrynol Pol 2010;61:169-173.
Davutoglu M, Ozkaya M, Guler E, et al. Plasma visfatin concentrations in childhood obesity: relationships to insulin resistance and anthropometric indices. Swiss Med Wkly 2009;139:22-27.
Berndt J, Klöting N, Kralisch S, et al. Plasma visfatin concentrations and fat-specific mRNA expression in humans. Diabetes 2005;54:2911-2916.
Pagano C, Pilon C, Olivieri M, et al. Reduced plasma visfatin/pre B-cell colony enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 2006;91:3165-3170.